Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $341 Million
- Q1 2025
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 9,130,465 shares of DYN stock, worth $130 Million. This represents 27.97% of its overall portfolio holdings.
Number of Shares
9,130,465
Previous 8,019,354
13.86%
Holding current value
$130 Million
Previous $189 Million
49.45%
% of portfolio
27.97%
Previous 31.16%
Shares
6 transactions
Others Institutions Holding DYN
# of Institutions
216Shares Held
116MCall Options Held
322KPut Options Held
66.2K-
Janus Henderson Group PLC London, X010.4MShares$147 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$138 Million2.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.41MShares$105 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$105 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$77.7 Million13.81% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $737M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...